Abbott Laboratories (ABT) Receives Price Target

Abbott Laboratories (ABT) : 11 investment research analysts covering Abbott Laboratories (ABT) have an average price target of $48.82 for the near short term. The highest target price given by the Brokerage Firm to the stock is $52 and the lowest target is $45 for the short term. Analysts expect the variance to be within $1.78 of the average price.

Abbott Laboratories (ABT) : 10 brokerage houses believe that Abbott Laboratories (ABT) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Abbott Laboratories (ABT). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 15 Wall Street Analysts endorse the stock as a Buy with a rating of 1.6.


Also, Major Brokerage house, Jefferies maintains its ratings on Abbott Laboratories (NYSE:ABT). In the latest research report, Jefferies raises the target price from $49 per share to $52 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on August 4, 2016.

Abbott Laboratories (NYSE:ABT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $41.92 and $41.74 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $42.34. The buying momentum continued till the end and the stock did not give up its gains. It closed at $42.30, notching a gain of 0.67% for the day. The total traded volume was 10,739,240 . The stock had closed at $42.02 on the previous day.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.